A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Progression-free survival (PFS) as assessed by the investigator per modified RECIST version 1.1
until disease progression, up to 1 year
No
Gallia Levy, M.D., Ph.D.
Study Director
Genentech
United States: Food and Drug Administration
GDC4950g
NCT01437566
October 2011
September 2015
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Albany, Georgia 31701 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
McLean, Virginia 22101 | |
Kansas City, Kansas 66160 | |
Hackensack, New Jersey 07601 | |
Boston, Massachusetts | |
Charleston, South Carolina | |
Washington, District of Columbia |